Published in final edited form as:

Vaccine. 2018 November 12; 36(46): 6988–6994. doi:10.1016/j.vaccine.2018.09.070.

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection

Hannah E. Gerretsen^a, Stefania Capone^b, Alessandra Vitelli^b, Laura S. Reyes^a, Amber Thompson^a, Claire Jones^a, Christopher A. Green^a, Andrew J. Pollard^a, Charles J. Sande^{a,c,*}

^aOxford Vaccine Group, Department of Paediatrics, and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford OX3 7LE, UK

^bReiTheraSRL, VialeCittàd' Europa679, 00144 Rome, Italy

^cKEMRI-Wellcome Trust Research Programme, Bofa Road, Kilifi, Kenya

Abstract

Introduction—Respiratory syncytial virus (RSV) is the single most important cause of severe respiratory illness in infants. There is no effective vaccine and the only effective treatment available is the monoclonal antibody palivizumab which reduces the risk of severe RSV disease in prematurely born infants. However, palivizumab is too costly to allow for wide implementation and thus treatment is restricted to supportive care. Despite extensive efforts to develop a vaccine, progress has been hindered by the difficulty in measuring and assessing immunological correlates of RSV vaccine efficacy in the presence of high levels of pre-existing RSV antibodies.

Methods—Here we describe a new method for measuring the functional activity of antibodies induced by vaccination distinct from pre-existing antibodies. Antibodies in lymphocyte supernatants (ALS) from the cultured peripheral blood mononuclear cells (PBMCs) of young adults who had recently been vaccinated with a novel RSV candidate vaccine were directly assayed for virus neutralising activity. An ELISA method was used to measure antibodies in nasal and serum samples and then compared with the adapted ALS based method.

Results—There was a wide background distribution of RSV-specific antibodies in serum and nasal samples that obscured vaccine-specific responses measured two weeks after vaccination. No RSV-specific antibodies were observed at baseline in ALS samples, but a clear vaccine-specific antibody response was observed in ALS seven days after the administration of each dose of vaccine. These vaccine-specific antibodies in ALS displayed functional activity *in vitro*, and quantification of this functional activity was unperturbed by pre-existing antibodies from natural

*Corresponding author at: KEMRI-Wellcome Trust Research Programme, P.O. Box 230 – 80108, Kilifi, Kenya. csande@kemri-wellcome.org (C.J. Sande).

Conflicts of interest

A.J.P. has previously conducted clinical trials of vaccines on behalf of Oxford University funded by GlaxoSmithKline Biologicals SA and ReiThera SRL but does not receive any personal payments from them. A.J.P. is the chair of the UK Department of Health's (DH) Joint Committee on Vaccination and Immunisation (JCVI), but the views expressed in this manuscript do not necessarily represent the views of JCVI or DH.

exposure. The results demonstrate a promising new approach for assessing functional immune responses attributed to RSV vaccines.

Keywords

Respiratory syncytial virus; Antibodies; Plasmablasts; Antibodies in lymphocyte supernatant

1 Introduction

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants, elderly adults and immunocompromised individuals [1–8]. Severe infections can cause bronchiolitis in infants [9,10] and are now recognised as a predisposing factor for the development of respiratory illness later in life [11–14]. Currently, there are no licensed vaccines or clinically effective antiviral therapies. Management of severe paediatric infections is purely supportive, and includes the use of supplemental oxygen [15–17].

At present, there are over 60 active RSV vaccine development programmes, whose target populations range from young infants to pregnant women and elderly adults [18–21]. Development of vaccines for each group presents unique challenges [22]. The early peak incidence of severe RSV disease (~2.5 months of age) severely limits the window for paediatric intervention [23,24], while the onset of T cell immunosenescence may hinder the development of sufficiently immunogenic vaccines for the elderly [25].

Many of the populations in which RSV vaccine trials are typically conducted, have high levels of pre-existing, RSV-specific antibody. Many phase I RSV vaccine trials are conducted in young healthy adults, who exhibit high levels of RSV-specific antibody as a result of recurrent natural exposure [26,27]. In the case of elderly adults, although previous studies have clearly demonstrated that elderly adults with severe RSV have higher levels of neutralising antibody relative to age-matched controls [28], in general, elderly adults retain high titres of RSV-specific antibodies at levels that are comparable to young healthy adults [25,29].

In the case of infants, previous reports have shown that the peak incidence of paediatric RSV disease occurs in RSV naïve infants, within the first three months and coincides with a period in which high levels of pre-existing antibody are present [23,30–32]. In these children, the source of pre-existing antibody is vertically transferred maternal antibodies that are present at relatively high levels during neonatal life [33].

Therefore, in the context of vaccine trials in which neonates, young or elderly adults are targeted for recruitment, distinguishing between RSV-specific antibodies that are induced by a vaccine and pre-existing antibodies induced by natural infection presents considerable difficulty. In trials of live attenuated RSV vaccines in RSV naïve infants – with high levels of maternally derived RSV antibody – despite evidence of protection against challenge with a second dose of vaccine, there was little evidence of a substantial fold increase in serum neutralising antibody following vaccination [34].

The most widely accepted correlate of protective immunity against severe RSV infection is serum neutralising antibody. In vaccine trials, this putative correlate of vaccine immunogenicity is typically characterised by representing the fold change from baseline in the titre of neutralising antibody. The accurate assessment of vaccine-induced antibodies has been complicated by the high baseline titre of pre-existing antibodies due to natural exposure to the virus [26]. Assays –such as serum-based ELISA and serumbased neutralisation tests – that are incapable of making the distinction between natural and vaccine-induced antibody may underestimate vaccine immunogenicity and negatively impact continued product development. In this project we sought to address this problem by developing an objective method of quantifying vaccine-induced antibodies distinct from pre-existing, naturally acquired antibodies in healthy adults. Peripheral blood mononuclear cells (PBMCs) were cultured *in vitro* and antibodies produced by differentiated plasmablasts were detected in the culture supernatant. Here we show that vaccine-specific antibodies in the lymphocyte supernatants (ALS) of vaccinated individuals can be functionally characterised separately from pre-existing antibodies derived from previous antigenic exposure. The results demonstrate a promising new approach for assessing vaccine immunogenicity and will be useful in the development of RSV vaccines.

2 Materials and methods

2.1 Study design and population

A single centre phase I, dose-escalation, open-label clinical trial (RSV001) was conducted from April 2013 to March 2014. The trial was registered with www.clinicaltrials.gov and EudraCT (ref NCT01805921 and 2011-003589-34, respectively). A total of 42 healthy adults (aged 18–50 years) were assigned to one of four study groups and received two doses of candidate vaccine in a prime/boost combination [26]. The experimental vaccines were genetically modified viral vectored vaccines (PanAd3-RSV or MVA-RSV) that each expressed the same three RSV proteins: F, M2-1 and N. Vaccines were administered in a prime/boost regime as seen in Fig. 1. Written informed consent was obtained from all volunteers prior to recruitment into the study. The construction and preclinical evaluation of PanAd3-RSV and MVA-RSV, the clinical trial protocol and results of the phase I (first-in-man) safety and immunogenicity trial are published elsewhere [26,35–37]. Four time points were evaluated for each individual: (i) prevaccination baseline, (ii) one (ALS assays) or two weeks (serum and nasal antibody assays) after the first (prime) vaccine dose, (iii) pre boost (just before the booster vaccine) and (iv) post boost (one and two weeks for ALS and serum/nasal antibody assays, respectively). Ethical approval for the conduct of the trial was obtained from the United Kingdom National Research Ethics Service (NRES) Berkshire (ref 13/SC/0023).

2.2 PBMC culture for isolation of antibodies in lymphocyte supernatants (ALS)

Blood samples for PBMC isolation were collected in tubes containing heparin: 400 µL of heparin per 50 ml of whole blood. PBMCs were isolated within 6 h of sample collection. Heparinized blood was mixed with an equivalent volume of R0 (RPMI containing an antibiotic - penicillin/streptomycin - and L-glutamine, stored at 4 °C) and PBMCs separated by density centrifugation using Lymphoprep (Alere). Isolated PBMCs were cryopreserved in

Recovery Cell Freezing Medium [10% dimethyl sulfoxide (DMSO) and calf serum, Invitrogen] and archived in vapour phase nitrogen. Cells were stored in vapour phase nitrogen for about 1 year prior to the analysis described in this report. Serum samples were obtained by centrifugation of whole blood collected in clotted tubes and then cryopreserved. To conduct ALS assays, cells were rapidly thawed in a 37 °C water bath before re-suspension in R10 media (RPMI media containing 10% foetal calf serum, penicillin/streptomycin and L-glutamine). The cells were centrifuged at 1500 rpm for 10 min, after which the media was discarded and the cell pellets reconstituted in 1 ml of R10. Reconstituted cells were counted using an automated cell counter (Scepter, Merck Millipore) and cell densities readjusted to 1×10^6 cells/ml by adding the appropriate volume of R10. 1 ml of PBMCs (1×10^6 cells in R10) were added to the wells of a 12-well tissue culture plate (Nunc) and incubated at 37 °C in a 5% CO₂ humidified incubator for 72 h. Following this incubation period, cells were pelleted by centrifugation (1500 rpm for 10 min) and the supernatants harvested and stored at -80 °C until they were ready for use.

2.3 Enzyme linked immunosorbent assays (ELISAs) for the detection of RSV F-specific antibodies in serum, nasal samples and ALS

Ninety six-well microtitre plates (Nunc Maxisorp) were coated overnight at 4 °C with 5 µg/mL recombinant F protein antigen (Sinobiological) in PBS for serum and ALS ELISAs and 20 µg/mL for ELISAs utilising nasal samples (which were collected using midturbinate swabs and eluted in Copan Universal Transport Medium kit - Copan Diagnostics Inc). 200 µL of blocking buffer (5% milk in PBS) was then added to each well and the plates incubated for one hour (37 °C humidified incubator). For the serum ELISAs, 50 µL of a 1:50 serum dilution was added to each well, while for the ALS and nasal ELISAs, undiluted samples were added to respective wells. The plates were then incubated for one hour as above and then washed three times with 200 µL/well PBS. 100 µL/well of 1:1000 dilutions of goat anti-human IgA (AbD Serotec) and IgG antibodies (Sigma) conjugated to horseradish peroxidase (HRP) (AbD Serotec) in blocking buffer were added to each well and incubated for one hour as above. Plates were then washed three times and developed using 100 µL/well Tetramethylbenzidine substrate - TMB (Sigma-Aldrich). After 5 min incubation in the dark, the reaction was terminated with 50 µL/well 2 M H₂SO₄. The plates were read using Biotek Elx808 absorbance microplate reader at an absorbance of 450 nm.

2.4 Plaque reduction neutralisation assay

Detection and quantification of neutralising antibodies in ALS samples was done by adding 25 plaque forming units (pfu) of the A2 strain of RSV to a doubling dilution series of ALS ranging from 1:2 to 1:256. 50 µL of this reaction mixture (25 µL A2-RSV containing 25pfu and 25 µL ALS) was then added to a confluent monolayer of HEp-2 cells in 96 well tissue culture plates (Falcon). The plates were incubated for 24 h to allow for un-neutralised virus to infect the HEp-2 cells. After the incubation period, the cells were washed once with PBS and 200 µL of a carboxymethylcellulose (CMC) overlay (1% CMC in R10) was added to each well and the plates incubated for 72 h (37 °C, 5% CO₂ and 95% humidity). After this incubation the cells were washed once with PBS and fixed for 10 min using cold acetone/methanol (80%/20% v/v). 100 µL/well of a 1:400 dilution of a mouse anti-RSV antibody (Novacastra, Leica) in PBS was added to each well and the plates incubated at 4 °C for 24 h.

The plates were then washed three times with PBS, followed by the addition of a 1:1000 dilution of an HRP-conjugated goat anti-mouse IgG antibody (Biorad). After a 1 h incubation at room temperature, plates were washed three times with PBS and developed using 3,9-aminoethylcarbazole (AEC) substrate (Sigma). The reaction was stopped after 30 min by washing once with PBS. The plaques were enumerated using an automated ELI-Spot reader (AID counter version 5). Calculation of plaque reduction neutralising antibody titres (PRNT) was done using the Spearman-Kärber method [38].

2.5 Statistical analysis

GraphPad Prism 6 (GraphPad Software, USA) and R statistical software were used to perform data analysis. The difference between the mean antibody levels at different time points was compared using a non-parametric paired *t* test (Wilcoxon test).

3 Results

3.1 Analysis of post vaccination antibody responses in sera and nasal samples

The baseline distribution of RSV-specific IgA and IgG antibody from serum and nasal samples was representative of the background natural immunity to RSV from repeated seasonal exposure. The natural humoral immunity from individual samples was highly variable (Fig. 2). After administration of both the prime and boost vaccine there was a small but statistically significant increase in the mean levels of serum IgA and IgG two-weeks after vaccination (Fig. 2). Despite this, there did not appear to be a clear difference in the distribution of these antibodies before and after vaccination since the pre-vaccination baseline distributions largely overlapped with responses measured two weeks after vaccination. The same dynamics were present after administration of the booster vaccine. When the data were stratified and analysed by individual prime/boost vaccination groups, most groups did not show significant increases in antibody concentration following vaccination (supplementary Fig. 1).

3.2 Analysis of responses to vaccination by measuring antibodies in lymphocyte supernatants

In contrast to the baseline concentrations of serum and nasal antibody, baseline ALS antibody levels were consistently low in all groups (Fig. 3 & supplementary Fig. 2). Seven days after vaccination there were significant increases in the mean levels of RSV-specific IgA and IgG ($p < 0.0001$ and $p = 0.004$, respectively, Fig. 3). When the data were analysed according to individual vaccination groups, there were significant increases in RSV-specific IgA ALS antibody in all groups after prime (group 1 $p = 0.04$, group 2 $p = 0.003$, group 3 $p = 0.04$, group 4 $p = 0.04$), and in all but one group (group 2 - PanAd3-RSV IM/PanAd3-RSV IM) after boost (group 1 $p = 0.02$, group 3 $p = 0.003$, group 4 $p = 0.008$, supplementary Fig. 2). Analysis of the IgG response in ALS showed a significant increase in two of the four groups following prime (group 2 $p = 0.007$ and group 4 $p = 0.03$) and in all but one group (group 2 - PanAd3-RSV IM/ PanAd3-RSV IM) following boost (group 1 $p = 0.04$, group 3 $p < 0.0001$, group 4 $p = 0.001$, supplementary Fig. 2). This pattern of response contrasted sharply from the responses to vaccination measured in nasal samples where a significant change in nasal IgG was only seen in group 2 following priming vaccine ($p = 0.009$) and a

significant nasal IgA change was only observed in group 2 following booster dose of the vaccine ($p = 0.049$, supplementary Fig. 1c and d).

Vaccine immunogenicity was also assessed by expressing the magnitude of antibody responses as fold changes in antibody level following vaccination (Fig. 4). In total, two volunteers seroconverted – i.e. showed a four-fold or greater increase – in serum IgA following priming vaccine, while none of the volunteers in the other groups achieved this serological threshold following the priming and booster vaccines (Fig. 4). Analysis of mucosal responses to vaccination showed that only two volunteers had a greater than four-fold increase in RSV-specific nasal IgG after priming dose of vaccine and one volunteer mounted a four-fold rise in nasal IgA following priming vaccine (Fig. 4). In contrast, when antibody responses to vaccination were evaluated in ALS, a large number of volunteers exhibited four-fold increases in RSV-specific IgG and IgA after both the priming and booster doses of vaccine. In a large proportion of volunteers RSV-specific IgA and IgG levels measured seven days after vaccination were over 10 fold higher than their respective baseline levels. In a smaller number of volunteers, increases in the post-vaccination levels of RSV IgG and IgA that were over 30-fold higher than baseline levels were observed (Fig. 4).

3.3 Analysis of the neutralising activity of ALS antibodies

To assess if ALS antibodies from vaccinated volunteers had functional activity, a modified plaque reduction neutralisation assay was developed (see materials and methods section) and used to determine the titre of RSV-specific neutralising antibodies in ALS. As shown in Fig. 5a, there was clear evidence that antibodies in the lymphocyte supernatant of a vaccinated volunteer were capable of mediating *in-vitro* neutralisation of RSV. Lower ALS dilutions exhibited potent neutralising activity, while at higher dilutions this neutralising effect was reduced in proportion to the extent of dilution (Fig. 5a). Using this assay, ALS neutralising activity was quantified in a subset of 10 volunteers from group 1 (PanAd3-RSV IM/MVA-RSV IM). Baseline neutralising antibody titres prior to the priming and booster doses of vaccine were measured and compared with neutralising antibody titres seven days after each vaccine. Relative to pre-vaccination levels, there was a statistically significant 2.6-fold increase in ALS plaque reduction neutralising antibody titre (PRNT) seven days after the priming vaccination (4.3 GMT vs 11.3 GMT; $p = 0.027$). However, the mean neutralising antibody response seven days after administration of the booster vaccine did not significantly differ from prevaccination levels measured prior to the administration of the booster vaccine (Fig. 5b).

4 Discussion

In this paper, we show for the first time that RSV vaccine-induced neutralising antibodies can be characterised separately from pre-existing serum and mucosal antibody by quantifying the functional activity of antibodies produced by antibody secreting cells in peripheral circulation. In the population of healthy young adults that was recruited into this trial, the assessment of vaccine-induced antibody responses in serum and nasal secretions was obscured by the high levels of pre-existing antibody, resulting from seasonal exposure to RSV. In contrast, RSV-specific antibodies in the culture supernatants of antibody-secreting

plasmablasts in peripheral circulation, could clearly be attributed to vaccination, since these cells were not present in circulation prior to vaccination. Plasmablasts are terminally differentiated antibody secreting cells that are derived from recently activated B cells and typically occur in circulation for a short duration following antigenic exposure and disappear shortly afterwards [39]. Due to their transient kinetics, they can be considered to be markers of recent antigenic exposure and can be used to distinguish between contemporary and historical exposures. In this study, these cells were obtained seven days after vaccination and maintained in an *in-vitro* culture in order to accumulate vaccine-specific antibodies in ALS samples. The samples were collected seven days after both priming and booster doses vaccination as this time point is well established to be the peak day of secondary immune responses [39–41]. In a previous study, we had characterised responses of vaccine recipients using ex-vivo B cell ELISpots [26]. The results of ALS ELISA responses to vaccination generally align with the results of the B-cell ELISpot assays. The baseline antibody levels to RSV F prior to the priming and booster doses of vaccine are low in both data sets. Similarly the anti RSV-F IgA and IgG responses to RSV-F, seven days after intramuscular priming by PanAd3-RSV was significantly higher than the baseline response, while the response to intranasal priming by PanAd3-RSV was comparatively modest in both data sets. In both assays, the IgA and IgG responses to an intramuscular boosting dose of PanAd3-RSV was significantly greater than the baseline antibody level in vaccines who had been primed intranasally with PanAd3-RSV but was no different from the baseline response in volunteers who had been primed intramuscularly with PanAd3-RSV. Similar concordance between ex-vivo B-cell ELISpots and ALS ELISA was observed in volunteers who were intranasally primed with PanAd3-RSV and who exhibited significant increases in IgA and IgG after intramuscular MVA boosting by both assays. Taken together these observations show that the ALS assay generally reflects the results of the more conventional ex-vivo B-cell ELISpot.

The results of the ALS-based assay further demonstrate that the high levels of baseline serum antibody that are typically observed in RSV vaccine trials of diverse target populations can be largely abrogated by evaluating vaccine-induced antibody responses using the culture supernatants of peripheral plasmablasts or ALS samples. In the data presented, the ability of the ALS-based assay to identify vaccine-specific responses was highlighted by a comparative analysis of the fold change in RSV F-specific antibody levels after vaccination. While most volunteers had only modest post-vaccination fold increases in serum and nasal antibody, most volunteers exhibited a four-fold or greater increase in the levels of ALS IgA and IgG (Fig. 4). Thus the recurring problem of failing to observe changes in virus-specific antibody post vaccination can be addressed by the use of ALS samples to address the influence of pre-existing antibody on measurements of vaccine-induced antibody.

The novel method presented here of assessing functional immunogenicity to an experimental RSV vaccine can be used in future vaccine trials targeting different population groups. Many target populations for RSV vaccination – neonates, pregnant women, the elderly – will typically have high levels of baseline RSV-specific antibody prior to vaccination. Previous trials that have sought to quantify functional antibody responses to experimental RSV vaccines have faced the challenge of quantifying vaccineinduced humoral immunity over a

background of high levels of pre-existing antibody. For instance, a live-attenuated vaccine tested in infants failed to induce any significant increases in antibody titres post vaccination [34]. Similarly, only 22% of young healthy adults and 16% of elderly patients who received a live-attenuated RSV vaccine developed significant antibody responses [42]. Recently, a phase I trial found that a RSV F nanoparticle vaccine induced only modest responses in a group of older adults [43].

Critically, we demonstrate that RSV-specific antibodies in ALS could be functionally assayed for neutralising activity against live RSV. As yet it is unclear whether this assay could be used to assess the extent to which vaccine candidates offer protection to future infection. This was not the aim of this study using phase I data. However, it would be interesting to see whether an ALS based approach could be used in future studies to assess protection to vaccination. Ideally, this method would be applied in large phase III trials to properly address whether this is possible. Among the potential limitations of the ALS method in the context of vaccine trials are the requirement for an additional blood draw for isolation of PBMCs for the assay. Also, being moderately labour-intensive, the assay may introduce additional complexities to trial protocols, particularly large phase III trials.

In conclusion, as the portfolio of RSV vaccine candidates emerging from the preclinical stages increases, this novel ALS-based approach can be used to provide an unambiguous estimation of a critical marker of vaccine efficacy – virus neutralising antibody-by alleviating the effect of pre-existing antibody.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This study was supported and sponsored by ReiThera SRL (formerly Okairos SRL), the NIHR Oxford Biomedical Research, and salary support for C.S. (WT 091663MA) from the Wellcome Trust.

References

- [1]. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012; 380:2095–128. DOI: 10.1016/S0140-6736(12)61728-0 [PubMed: 23245604]
- [2]. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet* (London, England). 2010; 375:1545–55. DOI: 10.1016/S0140-6736(10)60206-1
- [3]. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng P-Y, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993–2008. *Clin Infect Dis*. 2012; 54:1427–36. DOI: 10.1093/cid/cis211 [PubMed: 22495079]
- [4]. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. *N Engl J Med*. 2005; 352:1749–59. DOI: 10.1056/NEJMoa043951 [PubMed: 15858184]

- [5]. Lee N, Lui GCY, Wong KT, Li TCM, Tse ECM, Chan JYC, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. *Clin Infect Dis*. 2013; 57:1069–77. DOI: 10.1093/cid/cit471 [PubMed: 23876395]
- [6]. Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P, et al. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. *BMC Infect Dis*. 2014; 14:665.doi: 10.1186/s12879-014-0665-2 [PubMed: 25494918]
- [7]. Renaud C, Xie H, Seo S, Kuypers J, Cent A, Corey L, et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. *Biol Blood Marrow Transplant*. 2013; 19:1220–6. DOI: 10.1016/j.bbmt.2013.05.005 [PubMed: 23680472]
- [8]. Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. *Medicine (Baltimore)*. 1989; 68:269–81. [PubMed: 2677595]
- [9]. Miller EK, Gebretsadik T, Carroll KN, Dupont WD, Mohamed YA, Morin L-L, et al. Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. *Pediatr Infect Dis J*. 2013; 32:950–5. DOI: 10.1097/INF.0b013e31829b7e43 [PubMed: 23694832]
- [10]. Vaccines MRCS on RSV. Respiratory syncytial virus infection: admissions to hospital in industrial, urban, and rural areas. Report to the Medical Research Council Subcommittee on Respiratory Syncytial Virus Vaccines. *Br Med J*. 1978; 2:796–8. [PubMed: 359099]
- [11]. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpfen JLL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *N Engl J Med*. 2013; 368:1791–9. DOI: 10.1056/NEJMoa1211917 [PubMed: 23656644]
- [12]. Sigurs N, Bj R. Respiratory Syncytial Virus Bronchiolitis in Infancy Is an Important Risk Factor for Asthma and Allergy at Age 7. *Am J Respiratory Crit Care Med*. 2000; 161:1501–7.
- [13]. Pullan CR, Wheezing Hey EN. asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. *Br Med J (Clinical Res Ed)*. 1982; 284:1665–9.
- [14]. Krishnamoorthy N, Khare A, Oriss TB, Raundhal M, Morse C, Yarlagadda M, et al. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. *Nat Med*. 2012; 18:1525–30. DOI: 10.1038/nm.2896 [PubMed: 22961107]
- [15]. Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. *J Pediatr Pharmacol Ther*. 2009; 14:75–85. DOI: 10.5863/1551-6776-14.2.75 [PubMed: 23055894]
- [16]. Panitch HB. Respiratory syncytial virus bronchiolitis: supportive care and therapies designed to overcome airway obstruction. *Pediatr Infect Dis J*. 2003; 22:S83–7. [PubMed: 12671457]
- [17]. Diagnosis and management of bronchiolitis. *Pediatrics*. 2006; 118:1774–93. DOI: 10.1542/peds.2006-2223 [PubMed: 17015575]
- [18]. PATH. Respiratory syncytial virus. Vaccine development against a major cause of childhood respiratory illness. 2015
- [19]. U.S. National Institutes of Health. 51 studies found for: “respiratory syncytial virus” and “vaccine”. 2015
- [20]. Drysdale SB, Sande CJ, Green CA, Pollard AJ. RSV vaccine use – the missing data. *Expert Rev Vaccines*. 2015; 584:1–4. DOI: 10.1586/14760584.2016.1114419
- [21]. Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. *J Pediatr*. 2000; 137:865–70. [PubMed: 11113845]
- [22]. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. *Immunol Rev*. 2011; 239:149–66. DOI: 10.1111/j.1600-065X.2010.00972.x [PubMed: 21198670]
- [23]. Sande CJ, Cane PA, Nokes DJ. The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. *Vaccine*. 2014; 32:4726–9. DOI: 10.1016/j.vaccine.2014.05.038 [PubMed: 25005882]
- [24]. Glezen WP. Risk of primary infection and reinfection with respiratory syncytial virus. *Arch Pediatr Adolesc Med*. 1986; 140:543.doi: 10.1001/archpedi.1986.02140200053026

- [25]. Cherukuri A, Patton K, Gasser RA, Zuo F, Woo J, Esser MT, et al. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. *Clin Vaccine Immunol.* 2013; 20:239–47. DOI: 10.1128/CI.00580-12 [PubMed: 23239796]
- [26]. Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KS, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. *Sci Transl Med.* 2015; :7.doi: 10.1126/scitranslmed.aac5745.300ra126
- [27]. Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. *Vaccine.* 2013; 31:524–32. DOI: 10.1016/j.vaccine.2012.11.009 [PubMed: 23153449]
- [28]. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. *J Infect Dis.* 2004; 190:373–8. DOI: 10.1086/421524 [PubMed: 15216475]
- [29]. Walsh EE, Falsey AR. Age related differences in humoral immune response to respiratory syncytial virus infection in adults. *J Med Virol.* 2004; 73:295–9. DOI: 10.1002/jmv.20090 [PubMed: 15122807]
- [30]. Ochola R, Sande C, Fegan G, Scott PD, Medley GF, Cane PA, et al. The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. *PLoS ONE.* 2009; 4doi: 10.1371/journal.pone.0008088e8088
- [31]. Nokes DJ, Okiro EA, Ngama M, Ochola R, White LJ, Scott PD, et al. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya. *Clin Infect Dis.* 2008; 46:50–7. DOI: 10.1086/524019 [PubMed: 18171213]
- [32]. Nokes DJ, Ngama M, Bett A, Abwao J, Munywoki P, English M, et al. Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. *Clin Infect Dis.* 2009; 49:1341–9. DOI: 10.1086/606055 [PubMed: 19788358]
- [33]. Atwell JE, Thumar B, Robinson LJ, Tobby R, Yambo P, Ome-Kaius M, et al. Impact of placental malaria and hypergammaglobulinemia on transplacental transfer of respiratory syncytial virus antibody in Papua New Guinea. *J Infect Dis.* 2015; :213.doi: 10.1093/infdis/jiv401.jiv401 [PubMed: 25637350]
- [34]. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Boyce TG, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. *J Infect Dis.* 2000; 182:1331–42. DOI: 10.1086/315859 [PubMed: 11010838]
- [35]. Taylor G, Thom M, Capone S, Pierantoni A, Guzman E, Herbert R, et al. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections. *Sci Transl Med.* 2015; 7:1–14.
- [36]. Pierantoni A, Esposito ML, Ammendola V, Napolitano F, Grazioli F, Abbate A, et al. Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates. *Mol Ther Methods Clin Dev.* 2015; 2:15018.doi: 10.1038/mtm.2015.18 [PubMed: 26015988]
- [37]. Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, et al. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2–1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 cl. *BMJ Open.* 2015; 5doi: 10.1136/bmjopen-2015-008748e008748
- [38]. Cohen BJ, Audet S, Andrews N, Beeler J. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. *Vaccine.* 2007; 26:59–66. DOI: 10.1016/j.vaccine.2007.10.046 [PubMed: 18063236]
- [39]. Blanchard-Rohner G, Pulickal AS, Jol-van Der Zijde CM, Snape MD, Pollard AJ. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. *Blood.* 2009; 114:4998–5002. DOI: 10.1182/blood-2009-03-211052 [PubMed: 19843885]
- [40]. Kelly DF, Snape MD, Perrett KP, Clutterbuck EA, Lewis S, Blanchard Rohner G, et al. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. *Immunology.* 2009; 127:134–43. DOI: 10.1111/j.1365-2567.2008.02934.x [PubMed: 19175802]

- [41]. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehlinghaus G, et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. *Blood*. 2005; 105:1614–21. DOI: 10.1182/blood-2004-07-2507 [PubMed: 15507523]
- [42]. Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PPF-2) in healthy young and older adults. *Vaccine*. 2000; 18:1763–72. [PubMed: 10699324]
- [43]. Fries L, Shinde V, Stoddard JJ, Thomas DN, Kpamegan E, Lu H, et al. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. *Immun Ageing*. 2017; :14.doi: 10.1186/s12979-017-0090-7 [PubMed: 28642802]

Fig. 1.

An overview of the vaccination scheme followed in the phase I RSV clinical trial: Each participant was assigned to one of four groups. Each group received the boost vaccine eight weeks post prime vaccination, except for group two (*) which received the booster four weeks post prime. Number of participants in each group: $n = 11$ for group 1; $n = 10$ for group 2; $n = 10$ for group 3; $n = 11$ for group 4 ($n = 10$ for all groups after boost due to 2 withdrawals and replacement, per protocol).

Fig. 2.

Antibody responses in nasal and serum samples. The relative distributions of RSV F-protein specific IgA and IgG in serum and nasal samples are shown at different time points. The error bars represent the mean antibody level with the 95% confidence intervals (CI). *ns – not significant.

Fig. 3.

ALS IgG and IgA levels before and after priming and booster vaccinations are shown. Dotted lines represent a response threshold (mean of baseline antibody levels + 3 standard deviations) determined to differentiate between actual responses and background signals. The error bars represent the mean with the 95% CI.

Fig. 4.

The magnitude of the IgG and IgA response to vaccination was expressed as fold change in RSV-specific antibody level, one (ALS) or two (serum/nasal samples) weeks after the priming and booster doses of vaccine. The dotted line represent a four- fold changes in antibody level. The numbers and corresponding proportions of volunteers who seroconverted are shown above each group.

Fig. 5.

The functional activity of antibodies in ALS was quantified using a modified plaque reduction neutralization assay. ALS was used to neutralize RSV in an *in vitro* HEP-2 cell culture. Each plaque (red spot) represents un-neutralised virus. (a) ALS obtained from a patient vaccinated with PanAd3-RSV was diluted over an 8 series dilution range from 1:2 to 1:256 and each dilution was mixed with ~25 plaque forming units per well of RSV. Lower dilutions of ALS mediated potent neutralization of RSV, while at higher dilutions, this neutralization effect was diminished in proportion to the dilution. (b) The functional antibody response to vaccination was analysed in individuals vaccinated with PanAd3-RSV IM/MVA-RSV IM. At the pre-prime, pre-boost baseline and one week post boost time points, no significant in-vitro neutralization of RSV was observed. However, two weeks after PanAd3-RSV IM, a number of individuals had significant neutralizing antibody responses. The mean and 95% confidence limits are shown on each group. The dotted line is the mean of the pre-vaccination baseline plus three standard deviations. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)